Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Clinical trial NCT05907759 · RECRUITING
Trial details
- NCT number
- NCT05907759
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-10
- Primary completion
- 2034-08-01
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.